Protagonist Therapeutics, Inc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Leerink Partners selected Nektar Therapeutics (NKTR), Protagonist Therapeutics (PTGX), and Shattuck Labs (STTK) as top picks in emerging immunology. The firm highlighted NKTR's phase 3 asset rezpegaldesleukin for atopic dermatitis. PTGX and STTK were also noted for their potential.
UBS initiated coverage on Protagonist Therapeutics (PTGX) with a buy rating and $184 price target, citing drug potential. The stock is up 64.56% YTD. UBS highlights PN-881 as a key driver and expects upward revisions to Mimrylo royalties. Other analysts have also raised price targets following FDA approvals of Mimrylo and Icotyde.
Ali Asif (Chief Financial Officer) sold 58,629 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $141.78 ($141.77–$141.78, $8.31M total) across 2 trades on 2026-09-30 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PTGX (Protagonist Therapeutics, Inc). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent PTGX coverage spans regulation, financial news and insider activity.
In the last 30 days, PTGX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($8.3M). The most active reporter was Ali Asif, Chief Financial Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst coverage may improve market perception and support price gains.
Street initiation frames PTGX as undervalued versus its pipeline and Mimrylo royalty revisions, supporting bullish positioning.
The insider sale may signal reduced confidence from the CFO and could pressure the stock price.
The insider sale may signal confidence in the company's valuation but also adds supply pressure.
Large insider sell may signal confidence concerns, potentially pressuring the stock lower.
AlphAI scores every news story that mentions PTGX with an AI model for sentiment and relevance, and aggregates insider trades from Protagonist Therapeutics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Leerink Partners selected Nektar Therapeutics (NKTR), Protagonist Therapeutics (PTGX), and Shattuck Labs (STTK) as top picks in emerging immunology. The firm highlighted NKTR's phase 3 asset rezpegaldesleukin for atopic dermatitis. PTGX and STTK were also noted for their potential.
1 min readUBS initiated coverage on Protagonist Therapeutics (PTGX) with a buy rating and $184 price target, citing drug potential. The stock is up 64.56% YTD. UBS highlights PN-881 as a key driver and expects upward revisions to Mimrylo royalties. Other analysts have also raised price targets following FDA approvals of Mimrylo and Icotyde.
3 min readAli Asif (Chief Financial Officer) sold 58,629 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $141.78 ($141.77–$141.78, $8.31M total) across 2 trades on 2026-09-30 under a Rule 10b5-1 trading plan.
1 min readProtagonist Therapeutics (PTGX) CEO Dinesh V. Patel exercised 125,000 stock options at $21.58 per share and sold the shares over three days in September 2026 under a 10b5-1 plan. The weighted average sale prices were $145.87, $146.18, and $144.10 per share, respectively, totaling approximately $18.24M in gross proceeds.
2 min readPATEL DINESH V PH D (President and CEO) sold 125,000 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $145.92 ($144.10–$146.18, $18.24M total) across 3 trades over 2026-09-08 to 2026-09-10 under a Rule 10b5-1 trading plan.
1 min readProtagonist Therapeutics (PTGX) announced a $300M share repurchase program, funded by cash reserves and collaboration payments. The program may be executed through open market purchases or other transactions, with timing and amounts dependent on market conditions and other factors. As of June 30, 2026, the company had $849.5M in cash, cash equivalents, and marketable securities, excluding recent milestone payments.
2 min readProtagonist Therapeutics (PTGX) reported a $162.8M profit in Q2 2026, reversing a $34.8M loss from the prior year. The turnaround was driven by milestone payments for two drugs, ICOTYDE and rusfertide, with cash reserves reaching $849.5M. ICOTYDE, approved for psoriasis, triggered a $50M payment and potential $580M more from J&J. Rusfertide, awaiting FDA decision, has already brought in $200M from Takeda, with more milestones pending.
3 min readFDA approval of MIMRYLO triggered $275M in payments to Protagonist Therapeutics (PTGX), including a $200M opt-out fee and a $75M milestone. PTGX chose royalties over a 50:50 profit split with Takeda (TAK), opting for non-dilutive capital and lower execution risk. PTGX is eligible for up to $875M in additional milestones. The royalty structure ranges from 14% to 29% on worldwide net sales.
3 min readFDA approved Protagonist Therapeutics' and Takeda's drug rusfertide (Mimrylo) for polycythemia vera. Mimrylo, a weekly injection, controls red blood cell overproduction. Takeda has not disclosed the price. Analysts forecast peak sales up to $2B. Protagonist's stock has nearly tripled in a year. Mimrylo is Takeda's second of three anticipated drug launches.
2 min readProtagonist Therapeutics (PTGX) shares fell 6.5% after FDA approval of MIMRYLO, a drug for polycythemia vera, triggered a $275M milestone payment from Takeda. The approval validates Protagonist's peptide platform and could reshape treatment approaches. However, the stock's high valuation and concentration risk remain concerns.
3 min read
